naltrexone has been researched along with chloroquine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Fujii, H; Kobayashi, S; Miyata, Y; Nagase, H; Osa, Y; Takeuchi, T | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ajayi, AA; Onigbogi, O; Ukponmwan, OE | 1 |
| Ajayi, AA; Kolawole, BA; Udoh, SJ | 1 |
| Fujii, H; Kobayashi, S; Miyata, Y; Nagase, H; Takeuchi, T; Uenohara, Y | 1 |
| Aubé, J; Bohn, LM; Frankowski, KJ; Morgenweck, J; Prisinzano, TE | 1 |
| Abkhoo, A; Amiri, S; Boojar, MM; Dehpour, AR; Delazar, S; Hassanipour, M; Ostadhadi, S; Rahimi, N; Shirzadian, A | 1 |
| Fan, R; Feng, N; Gu, X; Guo, H; Jia, M; Li, J; Pei, J; Tian, X; Wang, X; Wang, Y; Yang, F; Zhang, S; Zhou, Y | 1 |
| Ahmadian, S; Dehpour, AR; Ebrahim-Habibi, A; Kashani-Amin, E; Malek, MR; Shafizadeh, M | 1 |
| Cowan, A; Dun, NJ; Inan, S | 1 |
| Boroujeni, SS; Dehpour, AR; Jafari, RM; Karimi, E; Maleki, A; Mohammadi, P; Sabzevari, O; Shafaroodi, H; Solaimanian, S | 1 |
1 review(s) available for naltrexone and chloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for naltrexone and chloroquine
| Article | Year |
|---|---|
Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching.
Topics: Administration, Oral; Adult; Animals; Antimalarials; Antipruritics; Area Under Curve; Chloroquine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Middle Aged; Naltrexone; Opioid Peptides; Parasitemia; Plasmodium; Promethazine; Pruritus; Receptors, Opioid, mu; Time Factors | 2004 |
14 other study(ies) available for naltrexone and chloroquine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudi.
Topics: Antimalarials; Benzylidene Compounds; Chloroquine; Drug Resistance; Molecular Structure; Naltrexone; Parasitic Sensitivity Tests; Plasmodium chabaudi; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship | 2011 |
Mechanisms of chloroquine-induced body-scratching behavior in rats: evidence of involvement of endogenous opioid peptides.
Topics: Animals; Antimalarials; Chloroquine; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Opioid Peptides; Pruritus; Rats | 2000 |
Investigation of 7-benzylidenenaltrexone derivatives as resistance reverser for chloroquine-resistant Plasmodium chabaudi.
Topics: Antimalarials; Benzylidene Compounds; Chloroquine; Drug Resistance; Glutathione Reductase; Naltrexone; Plasmodium chabaudi | 2012 |
Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Animals; Arrestins; beta-Arrestins; Chloroquine; Disease Models, Animal; Dose-Response Relationship, Drug; Guanidines; Isoquinolines; Male; Mice, Inbred C57BL; Mice, Knockout; Morphinans; Motor Activity; Naltrexone; Pruritus; Receptors, Opioid, kappa | 2015 |
Possible involvement of nitrergic and opioidergic systems in the modulatory effect of acute chloroquine treatment on pentylenetetrazol induced convulsions in mice.
Topics: Analgesics, Opioid; Analysis of Variance; Animals; Anticonvulsants; Arginine; Chloroquine; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanidines; Hippocampus; Indazoles; Male; Mice; Naltrexone; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitrites; Pentylenetetrazole; Seizures; Signal Transduction; Time Factors | 2016 |
The Protective Effects of Κ-Opioid Receptor Stimulation in Hypoxic Pulmonary Hypertension Involve Inhibition of Autophagy Through the AMPK-MTOR Pathway.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; AMP-Activated Protein Kinases; Animals; Antihypertensive Agents; Apoptosis; Autophagy; Blood Pressure; Cell Proliferation; Cells, Cultured; Chloroquine; Disease Models, Animal; Hypertension, Pulmonary; Male; Myocytes, Smooth Muscle; Naltrexone; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Signal Transduction; TOR Serine-Threonine Kinases | 2017 |
Investigating the role of endogenous opioid system in chloroquine-induced phospholipidosis in rat liver by morphological, biochemical and molecular modelling studies.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chloroquine; Disease Models, Animal; Fatty Liver; Glycine; Hippurates; Liver; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Naltrexone; Narcotic Antagonists; Opioid Peptides; Phospholipids; Rats; Receptors, Opioid, mu; Signal Transduction | 2020 |
Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.
Topics: Animals; Antipruritics; Behavior, Animal; Chloroquine; Deoxycholic Acid; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Mice; Nalbuphine; Naltrexone; Narcotic Antagonists; Pruritus; Receptors, Opioid, kappa; tat Gene Products, Human Immunodeficiency Virus | 2021 |
Opioidergic and nitrergic systems mediate the anticonvulsant effect of mefloquine and chloroquine on seizures induced by pentylenetetrazol and maximal electroshock in mice.
Topics: Animals; Anticonvulsants; Chloroquine; Disease Models, Animal; Electroshock; Mefloquine; Mice; Naltrexone; Nitrites; Pentylenetetrazole; Seizures | 2022 |